Several companies have received upgrades and initiations by reputable brokerage firms, investment firms, and analysts. These actions have generated interest in the market and provided price targets for each company, indicating potential upside. It's important to note that these targets are based on the views of the respective firms and analysts.

Iovance Biotherapeutics, Inc. (Nasdaq: IOVA), a biotechnology company focused on developing innovative cancer immunotherapies, received a positive boost as it was upgraded from Equal Weight to Overweight by Wells Fargo, accompanied by a price target increase from $11 to $17. 

On Tuesday, $IOVA closed at $8.85, surging by $1.30 or 17.22%. This upgrade suggests a potential upside of $8.15 or 92.09% based on the revised price target provided by Wells Fargo.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), a leading biotechnology company specializing in the discovery and development of transformative medicines for serious diseases, caught the attention of William Blair, which initiated coverage on the stock with an Outperform rating and a price target of $382. 

$VRTX experienced a slight decline of $4.69 or 1.42%, closing at $325.30 on Tuesday. Considering the given price target by William Blair, there is a potential upside of $56.70 or 17.47% for investors to consider.

Universal Health Services, Inc. (NYSE: UHS), a healthcare management company operating hospitals and healthcare facilities across the United States, saw an improvement in its rating and price target by SVB Securities, transitioning from Market Perform to Outperform and from $147 to $170 respectively. 

$UHS closed at $131.36 on Tuesday, indicating a gain of $3.38 or 2.64%. Based on the updated price target provided by SVB Securities, there is a potential upside of $38.64 or 29.42% for investors considering UHS.

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a clinical-stage biopharmaceutical company focused on developing novel therapies for immune and fibrotic diseases, garnered attention as RBC Capital Markets initiated coverage on the stock with an Outperform rating and a price target of $44. 

$VRDN closed at $23.99 on Tuesday, showing a modest increase of $0.26 or 1.10%. This initiatory coverage implies a potential upside of $20.01 or 83.46% based on the given price target by RBC Capital Markets.

It's worth noting that these assessments and price targets are based on the views and analyses of the respective firms and analysts mentioned. Investors should conduct their own research and consider various factors before making investment decisions.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)